Scholarlink

<p>Determining the clinical relevance of <i>BRCA2</i> variants of uncertain significance is critical for informed risk management. Recently, two saturation genome editing studies assessed the functional effects of all single nucleotide variants in the BRCA2 C-terminal DNA Binding Domain. To improve the accuracy of functional data used for ACMG/AMP variant classification, we combined results from these studies in four composite models and evaluated the performance of each model using variants with known classifications. Here, we show that an “Integrated VarCall Model”, which combined raw functional data for 6383 variants from the original studies, yielded 98.8% accuracy and out-performed the original studies and other combined data models. Incorporation of the “Integrated VarCall Model” functional data with other sources of evidence according to ClinGen <i>BRCA1/2</i> variant curation expert panel specifications resulted in classification of 5926 (92.8%) <i>BRCA2</i> variants as pathogenic (<i>n</i> = 735) or benign (<i>n</i> = 5191) and provides valuable insights for individuals with <i>BRCA2</i> variants.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combining multiplexed assays of variant effect for enhanced BRCA2 variant classification

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Chunling Hu,
  • Sounak Sahu,
  • Wenan Chen,
  • Melissa Galloux,
  • Marcy E. Richardson,
  • Megan F. Bishop,
  • Rachid Karam,
  • Tina Pesaran,
  • Jie Na,
  • Huaizhi Huang,
  • Jeffrey N. Weitzel,
  • Katherine N. Nathanson,
  • Siddhartha Yadav,
  • Nicholas J. Boddicker,
  • Susan M. Domchek,
  • Alvaro N. Monteiro,
  • Edwin S. Iversen,
  • Shyam K. Sharan,
  • Fergus J. Couch

摘要

Determining the clinical relevance of BRCA2 variants of uncertain significance is critical for informed risk management. Recently, two saturation genome editing studies assessed the functional effects of all single nucleotide variants in the BRCA2 C-terminal DNA Binding Domain. To improve the accuracy of functional data used for ACMG/AMP variant classification, we combined results from these studies in four composite models and evaluated the performance of each model using variants with known classifications. Here, we show that an “Integrated VarCall Model”, which combined raw functional data for 6383 variants from the original studies, yielded 98.8% accuracy and out-performed the original studies and other combined data models. Incorporation of the “Integrated VarCall Model” functional data with other sources of evidence according to ClinGen BRCA1/2 variant curation expert panel specifications resulted in classification of 5926 (92.8%) BRCA2 variants as pathogenic (n = 735) or benign (n = 5191) and provides valuable insights for individuals with BRCA2 variants.